• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, September 8, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Kleinberg secures $2.3 million to develop AI patients can use to manage their health

Bioengineer by Bioengineer
September 17, 2019
in Health
Reading Time: 4 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

With Kleinberg’s three new grants, she now has a total in $5.4 million for her research initiatives, which focus on useable artificial intelligence: information individual patients are able to use according to their lifestyle, beliefs and assumptions

IMAGE

Credit: Stevens Institute of Technology

Samantha Kleinberg, a computer scientist at Stevens Institute of Technology and pioneer in wearable technologies, has secured roughly $2.3 million in three new grants by the National Science Foundation and the National Institutes of Health to develop artificial intelligence that provides personalized information to patients so they can take an active part in managing their health.

“It’s usable AI,” said Kleinberg. “The amount of available data in health and medicine is overwhelming and not all of it is relevant or important for each individual. We combine computational work and the human elements of decision-making to give patients the information they need to actively decide, with their clinician, what their treatment plan should be.”

The new grants, which bring Kleinberg’s total research funding to $5.4 million, underscore a growing market where artificial intelligence and big data are providing added value to healthcare with a focus on diagnosis, treatment, patient monitoring and prevention.

A brief summary of each grant is below:

Uniting Causal and Mental Models for Shared Decision-Making in Diabetes; $917,879: National Science Foundation

Kleinberg will develop computational tools to personalize information patients with diabetes see in order to better decide on a treatment plan. This research is based on a longstanding model in healthcare known as shared decision-making approach, where a patient and clinician work together to understand the patient’s preferences and formulate a treatment plan. However, the efficacy of the model can be strained as each participant in the treatment plan–patient, doctor, other caregivers–holds different set of beliefs about disease and treatment, leading to different approaches that can derail results. Additionally, the amount of information given to patients can be too complex and include unnecessary details–which could lead to patients becoming overwhelmed or not understanding. Kleinberg, in collaboration with Jessecae Marsh, a cognitive scientist at Lehigh University, will also create training modules to educate clinicians about how patient beliefs influence trust and decision-making, as a way to facilitate optimal ways to share decision about treatment. Onur Asan, who heads the Humans-Systems Interaction Lab at Stevens, will serve as co-principal investigator.

Harnessing Patient Generated Data to Identify Causes and Effects of Nutrition during Pregnancy; $864,220: National Institutes of Health

During pregnancy, about 9 percent of women develop gestational diabetes. In collaboration with Andrea Deierlein, a nutritional and reproductive epidemiologist at New York University, Kleinberg will use patient-generated health data collected through wearing activity monitors, logging meals in real time using photos that parses out type of food and calories, or recording symptoms to capture what happens before illness develops. While type 2 diabetes typically develops over a long period of time, gestational diabetes occurs within a short, bracketed time period, making this the ideal population to study. Ultimately, the data aim to identify what factors cause this disease and will be used to identify targets for early interventions and to guide decisions during pregnancy.

Moving Beyond Knowledge to Action: Evaluating and Improving the Utility of Causal Inference; $499,454: National Science Foundation

In an effort to build artificial intelligence, researchers are developing algorithms that determine cause and effect and as such, have focused on developing methods to mine through data to find these causal structures. However, causes have been treated as the end goal, without addressing information that is most useful for patients i.e. what they can and/or are willing to act on to improve their health. Kleinberg wants to build artificial intelligence that’s useable for the benefit of patients.

For example, imagine monitoring a person with diabetes on their physical activity, food intake and stress levels. Perhaps all three variables coincide with high glucose or other adverse health outcomes. But which of these variable – activity, food intake, or stress – is actually causing the adverse health outcome? Current artificial intelligence is good at finding these correlations, but not as good as determining a causal structure. Moreover, artificial intelligence cannot determine which of these variables people are willing to – or able to – change in order to improve their heath. “Humans don’t just use data like a machine,” said Kleinberg. “They make decisions based on many things, including prior experiences and assumptions. So not all new information has the same impact on influencing a person’s decisions.”

The research will focus on understanding what makes the output of an algorithm useful to human decision-makers so that algorithms can be evaluated based on this ability, rather than the percent of causes they find or how fast algorithms accomplish a task. This will introduce new methods that make causal models more usable and personalized, leveraging these results to improve everyday decisions around treatment, diet and exercise.

###

Media Contact
Thania Benios
[email protected]

Original Source

https://www.stevens.edu/news/empowerment-through-big-data-kleinberg-secures-23-million-develop-ai-patients-can-use-manage-their

Tags: Algorithms/ModelsComputer ScienceDevelopmental/Reproductive BiologyDiabetesDiet/Body WeightExerciseNutrition/NutrientsTechnology/Engineering/Computer Science
Share12Tweet8Share2ShareShareShare2

Related Posts

Frailty Drives Gut Microbiome Imbalance and Heightens Post-Surgical GI Risks

September 8, 2025

New Pathway Fuels Cancer Cells with Acetyl-CoA

September 8, 2025

Enhancing Memory Through Targeted Training Techniques

September 8, 2025

Chitosan-Enhanced Therapy Reduces Epidural Scar Adhesions

September 8, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    56 shares
    Share 22 Tweet 14
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Frailty Drives Gut Microbiome Imbalance and Heightens Post-Surgical GI Risks

BMS-986504 Shows Lasting Efficacy in MTAP-Deleted NSCLC, Targeting EGFR and ALK-Positive Tumors

EA5181 Phase 3 Trial Shows No Overall Survival Advantage for Concurrent Plus Consolidative Durvalumab Over Consolidation Alone in Unresectable Stage 3 NSCLC

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.